ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal
The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases. Under the licensing deal signed earlier this year, Aligos granted Xiamen Amoytop Biotech exclusive rights to develop and sell its experimental hepatitis B treatment drug, pevifoscorvir sodium, in Greater China. Under the deal, Aligos is eligible for … Read more